Grace Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Stockholders held by Grace Therapeutics, Inc. on September 17, 2026. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol "GRCE".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders representing 61.28% of the 16,274,026 shares issued and outstanding participated in the meeting. The following proposals were acted upon:
- Proposal 1 (Election of Directors): All five nominees (Vimal Kavuru, A. Brian Davis, Prashant Kohli, S. George Kottayil, and Edward Neugeboren) were elected. Each received over 6 million votes "For" with minimal votes withheld.
- Proposal 2 (Say-on-Pay): The advisory vote to approve Named Executive Officer compensation was approved with 5,740,999 votes "For" versus 222,775 "Against".
- Proposal 3 (Auditor Ratification): Stockholders approved the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2027, with 9,878,292 votes "For".
- Proposal 4 (Say-on-Pay Frequency): Stockholders voted to hold future advisory votes on executive compensation annually. The "1 Year" option received 5,772,652 votes, significantly outpacing the 2-year and 3-year options.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, or contingencies. The Board has determined to include an annual stockholder advisory vote on executive compensation based on the results of Proposal 4.
Investor Verification Checklist
- Verify the total number of shares outstanding (16,274,026) and the record date (July 20, 2026) to confirm voting eligibility.
- Review the Definitive Proxy Statement on Schedule 14A filed on July 28, 2026, for detailed biographies of the elected directors and executive compensation specifics.
- Confirm the appointment of KPMG LLP as the auditor for the fiscal year ending March 31, 2027.
- Note the high number of broker non-votes (3,932,361) on director elections and executive compensation proposals, indicating significant shares held in street name where brokers lacked discretionary voting power.